COVID-19: Understanding the Granulocyte Response and Exploring Their Therapeutic Interventions.

Area of Science:

• Immunology
• Infectious Diseases
• Pathophysiology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, leading to immune dysregulation.
• Granulocytes (neutrophils, eosinophils, basophils) are key innate immune cells with roles in both protection and pathogenesis during infection.

Purpose of the Study:

• To review the complex roles of granulocytes in COVID-19.
• To explore how granulocyte activation impacts disease severity, including inflammation, cytokine storm, and tissue damage.
• To summarize therapeutic strategies targeting granulocyte pathways.

Main Methods:

• Literature review of granulocyte functions in COVID-19.
• Analysis of the impact of neutrophil extracellular traps (NETs) and granulocyte subtypes on thrombosis and acute respiratory distress syndrome.
• Examination of eosinophil and basophil roles in T helper 2-type and allergic responses.
• Summary of therapeutic interventions targeting granulocyte activation and signaling pathways.

Main Results:

• Neutrophil overactivation and NETs contribute to thrombosis and ARDS in COVID-19.
• Eosinophils and basophils modulate immune responses, potentially affecting disease progression or recovery.
• Various targeted therapies, including cytokine inhibitors and antihistamines, are being studied for their clinical outcomes.

Conclusions:

• Granulocyte dysregulation is central to COVID-19 immunopathology.
• Targeted immunomodulatory therapies offer potential for managing severe COVID-19.
• Balancing protective immunity with anti-inflammatory interventions is crucial for mitigating SARS-CoV-2 complications.